Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
For patients with acute respiratory tract infection, using procalcitonin levels to guide treatment decisions can reduce antibiotic use and improve survival, finds a meta-analysis in the Lancet Infectious Diseases. High procalcitonin levels can indicate a bacterial infection, while low levels can mean a viral or noninfectious cause.
Researchers examined 26 trials in which 6700 adults with clinically diagnosed respiratory infections were randomized to procalcitonin-guided therapy or a control group. Most trials included emergency department or hospitalized patients with lower respiratory infections, or ICU patients with sepsis resulting from respiratory infections; two trials included primary care patients with upper or lower respiratory infections.
Overall, 30-day mortality was significantly lower with procalcitonin-guided therapy than with control treatment (9% vs. 10%). The finding was seen in all clinical settings except primary care, where only one death occurred. Treatment failure was numerically lower with procalcitonin-guided therapy.
Procalcitonin-guided therapy led to fewer antibiotic prescriptions and shorter treatment duration.
The authors conclude: "When embedded in clinical algorithms, the use of procalcitonin has the potential to inform and improve care of patients with acute respiratory infections by reducing antibiotic exposure and the associated risk of developing subsequent antibiotic resistance and more importantly improving clinical outcomes."
Comment
LINK(S):
Lancet Infectious Diseases article (Free abstract)
Lancet Infectious Diseases comment (Subscription required)
Background: Physician's First Watch coverage of FDA approval of procalcitonin as biomarker to help guide antibiotic treatment (Free)